133 related articles for article (PubMed ID: 3782248)
21. Treatment of renal osteodystrophy with calciferol (vitamin D) and related steroids.
Brickman AS; Norman AW
Kidney Int; 1973 Aug; 4(2):161-7. PubMed ID: 4364427
[No Abstract] [Full Text] [Related]
22. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
Madsen S
Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
[No Abstract] [Full Text] [Related]
23. [The effects of CaCO3 on renal osteodystrophy--comparison of patients with chronic renal failure in the predialytic stage and patients undergoing maintenance hemodialysis].
Okada K; Kuno T; Yanai M; Maeda H; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1988 Aug; 30(8):1053-62. PubMed ID: 3244188
[No Abstract] [Full Text] [Related]
24. [Bone metabolism markers and bone histomorphometry in children with chronic renal failure in predialysis period during growth hormone treatment].
Pańczyk-Tomaszewska M; Ziółkowska H; Debiński A; Sawicki A; Zurowska A; Pietrzyk JA; Roszkowska-Blaim M
Pol Merkur Lekarski; 2000 Apr; 8(46):264-5. PubMed ID: 10897642
[TBL] [Abstract][Full Text] [Related]
25. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
26. Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
Kanis JA; Henderson RG; Heynen G; Ledingham JG; Russell RG; Smith R; Walton RJ
Arch Dis Child; 1977 Jun; 52(6):473-81. PubMed ID: 879833
[TBL] [Abstract][Full Text] [Related]
27. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
Massry SG; Goldstein DA; Malluche HH
Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
[No Abstract] [Full Text] [Related]
28. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
[TBL] [Abstract][Full Text] [Related]
29. Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure.
Witmer G; Margolis A; Fontaine O; Fritsch J; Lenoir G; Broyer M; Balsan S
Kidney Int; 1976 Nov; 10(5):395-408. PubMed ID: 794558
[TBL] [Abstract][Full Text] [Related]
30. Parathyroidectomy in uraemic hyperparathyroidism: a clinical study.
Taylor J; Gunn A; Mactier RA; Henderson IS; Stewart WK
Scott Med J; 1992 Feb; 37(1):18-21. PubMed ID: 1574690
[TBL] [Abstract][Full Text] [Related]
31. 25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients.
Coen G; Taccone-Gallucci M; Bonucci E; Bianchini G; Gallucci G; Lucentini G; Matteucci MC; Picca S; Casciani CU
Int J Artif Organs; 1979 Nov; 2(6):278-81. PubMed ID: 511368
[TBL] [Abstract][Full Text] [Related]
32. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure.
Andreoli SP; Dunson JW; Bergstein JM
Am J Kidney Dis; 1987 Mar; 9(3):206-10. PubMed ID: 3826069
[TBL] [Abstract][Full Text] [Related]
33. Can renal bone disease be prevented?
Shaldon S
Proc Eur Dial Transplant Assoc; 1973; 10(0):91-123. PubMed ID: 4808119
[No Abstract] [Full Text] [Related]
34. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)].
Chantraine JM; Davin JC; Lambrechts L; Heynen G
Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307
[TBL] [Abstract][Full Text] [Related]
35. Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.
Mak RH; Turner C; Thompson T; Powell H; Haycock GB; Chantler C
Br Med J (Clin Res Ed); 1985 Sep; 291(6496):623-7. PubMed ID: 3928054
[TBL] [Abstract][Full Text] [Related]
36. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
[TBL] [Abstract][Full Text] [Related]
37. [Influence of vitamin D therapy on renal osteodystrophy in children (author's transl)].
Bulla M; Stock GJ; Delling G; Hofmann H; Offermann G
Klin Wochenschr; 1980 Mar; 58(5):237-47. PubMed ID: 6249957
[TBL] [Abstract][Full Text] [Related]
38. [Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure].
Kanagawa S; Yosikawa Y; Dohi Y
Nihon Rinsho; 1991 Dec; 49 Suppl():770-4. PubMed ID: 1808348
[No Abstract] [Full Text] [Related]
39. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease.
Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424
[TBL] [Abstract][Full Text] [Related]
40. The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease.
Pierides AM; Ellis HA; Simpson W; Cook D; Kerr DN
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():109s-116s. PubMed ID: 606409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
